Table 2

Comparison of demographic data between female patients with elevated or normal PRL levels

FactorsElevated PRL
RIS/OLZ
(n=82/n=47)
Normal PRL
RIS/OLZ
(n=40/n=62)
Statistics
RIS/OLZ
P value
RIS/OLZ
Age, years46.50 (30, 58)/34 (27, 46)46(31, 53)/39 (26.75, 51.75)U=−0.68/0.620.499/0.536
Illness duration, years12.50 (5, 25)/5 (0.92, 12.55)12.50 (6.00, 25.75)/6 (1.24, 18.15)U=−0.20/1.170.840/0.243
Age of onset, years25.5 (20, 31.75)/25 (20, 34)25 (21,33)/25 (19.75, 34)U=0.43/−0.750.666/0.451
Medication time, years0.39 (0.08, 1.56)/0.07 (0, 0.71)0.08 (0, 1.81)/0.38 (0.01, 1.36)U=−2.57/1.830.010*/0.068
Body mass index, kg/m2 23.44 (21.26, 25.29)/23.49 (20.20, 26.23)25.18 (22.08, 27.38)/22.11 (20.56, 24.30)U=1.86/−0.730.060/0.466
Dose, mg/day4 (3, 6)/10 (10, 20)3 (2, 4)/10 (5, 15)U=−3.37/−2.510.001**/0.012*
Fasting plasma glucose, mmol/L5.26 (4.90, 5.49)/4.94 (4.44, 5.40)5.18 (4.65, 5.77)/5.21 (4.99, 5.59)U=−0.22/2.030.827/0.042*
Total cholesterol, mmol/L4.63 (0.86)/4.71 (0.93)4.50 (0.93)/4.59 (0.85)t=0.76/0.610.451/0.55
Triglycerides, mmol/L1.00 (0.70, 1.28)/1.16 (0.72, 1.78)1.25 (0.83, 1.70)/1.40 (0.97, 1.81)U=1.81/0.820.070/0.410
PRL, ng/mL78.31 (51.32, 136.29)/63.96 (40.09, 111.75)7.07 (3.69, 20.70)/12.43 (5.42, 17.76)————
  • Normal distribution (mean+SD).

  • Non-normal distribution (median (Q1, Q3)).

  • *p≤0.05

  • **p≤0.001

  • OLZ, olanzapine; PRL, prolactin; RIS, risperidone.